Document is current
Any future updates will be listed below
-
Authors
Bykov, Katsiaryna
Schneeweiss, Sebastian
Glynn, Robert J.
Mittleman, Murray A.
Bates, David W.
Gagne, Joshua J.
-
Funding
Funding for this research was provided by:
Agency for Healthcare Research and Quality (R01HS023122)
- License Information
-
More Information
Article History
First Online: 16 June 2017
Compliance with ethical standards
:
: This study was funded by the Agency for Healthcare Research and Quality (R01HS023122 [Gagne]).
: Katsiaryna Bykov is supported by an unrestricted training grant from Takeda to Harvard T.H. Chan School of Public Health. Sebastian Schneeweiss is consultant to WHISCON, LLC and to Aetion, Inc., a software manufacturer of which he also owns equity. He is principal investigator of investigator-initiated grants to the Brigham and Women’s Hospital from Bayer, Genentech and Boehringer Ingelheim unrelated to the topic of this study. Robert Glynn has received grants to his institution for research unrelated to the current study from AstraZeneca, Kowa, Novartis, and Pfizer. Murray Mittleman has no conflicts of interests directly related to the study. David Bates is a coinventor on Patent No. 6029138 held by Brigham and Women’s Hospital on the use of decision support software for medical management, licensed to the Medicalis Corporation, of which he also holds a minority equity. He serves on the board for SEA Medical Systems, which makes intravenous pump technology. He consults for EarlySense, which makes patient safety monitoring systems. Dr Bates receives equity and cash compensation from QPID, Inc., a company focused on intelligence systems for electronic health records. He receives cash compensation from CDI (Negev), Ltd, which is a not-for-profit incubator for health IT startups. He receives equity from Enelgy, which makes software to support evidence-based clinical decisions, ValeraHealth, which makes software to help patients with chronic diseases, Intensix, which makes software to support clinical decision making in intensive care, MDClone which takes clinical data and produces deidentified versions of it. Dr Bates’ financial interests have been reviewed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their institutional policies. Joshua Gagne was a principal investigator of a grant from Novartis Pharmaceuticals Corporation to the Brigham and Women’s Hospital for unrelated work. He is a consultant to Aetion Inc., a software company, and to Optum, Inc.
: Patient data was de-identified and the study was approved by the Brigham and Women’s Hospital institutional review board.
